TY - JOUR

T1 - Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata

T2 - A Systematic Review and Meta-analysis

AU - Sedeh, Farnam Barati

AU - Michaelsdóttir, Thorunn Elísabet

AU - Henning, Mattias Arvid Simon

AU - Jemec, Gregor Borut Ernst

AU - Ibler, Kristina Sophie

N1 - Publisher Copyright: © 2023, Medical Journals/Acta D-V. All rights reserved.

PY - 2023

Y1 - 2023

N2 - The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review fol-lowing Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane libra-ry. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alope-cia areata defined as a SALT score ≥ 50, oral deurux-olitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are requi-red to confirm these findings.

AB - The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review fol-lowing Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane libra-ry. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alope-cia areata defined as a SALT score ≥ 50, oral deurux-olitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are requi-red to confirm these findings.

KW - alopecia areata

KW - biological

KW - JAK inhibitors

KW - polygenic autoimmune disease

U2 - 10.2340/actadv.v103.4536

DO - 10.2340/actadv.v103.4536

M3 - Review

C2 - 36695751

AN - SCOPUS:85146875009

VL - 103

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

M1 - adv00855

ER -